SHANGHAI SERUM BIO-TECHNOLOGY CO., LTD. — Investor Relations & Filings
About SHANGHAI SERUM BIO-TECHNOLOGY CO., LTD.
Shanghai Serum Bio-Technology Co., Ltd. is a specialized biopharmaceutical enterprise focused on the research, development, and manufacturing of therapeutic biological products. The company primarily produces a range of antiserums and antitoxins, including specialized antivenoms for various snake species, tetanus antitoxins, and rabies immunoglobulins. Its product portfolio supports emergency medical care and infectious disease management. The organization maintains advanced production facilities compliant with Good Manufacturing Practice (GMP) standards to ensure the safety and efficacy of its biological treatments. By leveraging biotechnological innovation, the company serves clinical needs in healthcare sectors, providing critical life-saving interventions for envenomation and acute bacterial toxins.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| 赛伦生物：自愿披露关于抗蜂毒血清获得药物临床试验批准通知书的公告 | 2026-05-07 | Chinese | |
| 赛伦生物：2025年年度股东会会议资料 | 2026-05-06 | Chinese | |
| 赛伦生物：2025年度募集资金存放、管理与实际使用情况的专项报告 | 2026-04-24 | Chinese | |
| 赛伦生物：关于2025年度利润分配方案及2026年中期现金分红事项的公告 | 2026-04-24 | Chinese | |
| 赛伦生物：《董事、高级管理人员薪酬管理制度》（2026年4月） | 2026-04-24 | Chinese | |
| 赛伦生物：2025年度会计师事务所履职情况评估报告 | 2026-04-24 | Chinese |
Browse filings by year
5 years| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
15 filings
| |||||
| 44272310 | 赛伦生物：自愿披露关于抗蜂毒血清获得药物临床试验批准通知书的公告 | 2026-05-07 | Chinese | ||
| 44280333 | 赛伦生物：2025年年度股东会会议资料 | 2026-05-06 | Chinese | ||
| 39939478 | 赛伦生物：2025年度募集资金存放、管理与实际使用情况的专项报告 | 2026-04-24 | Chinese | ||
| 39939476 | 赛伦生物：关于2025年度利润分配方案及2026年中期现金分红事项的公告 | 2026-04-24 | Chinese | ||
| 39939472 | 赛伦生物：《董事、高级管理人员薪酬管理制度》（2026年4月） | 2026-04-24 | Chinese | ||
| 39939451 | 赛伦生物：2025年度会计师事务所履职情况评估报告 | 2026-04-24 | Chinese | ||
| 39939447 | 方正证券承销保荐有限责任公司关于上海赛伦生物技术股份有限公司2025年度持续督导工作现场检查报告 | 2026-04-24 | Chinese | ||
| 39939434 | 赛伦生物：2025年度内部控制审计报告 | 2026-04-24 | Chinese | ||
| 39939190 | 赛伦生物：2025年年度报告摘要 | 2026-04-24 | Chinese | ||
| 39939180 | 赛伦生物：关于续聘2026年度审计机构的公告 | 2026-04-24 | Chinese | ||
| 39939166 | 赛伦生物：2025年度会计师事务所对公司控股股东及其他关联方占用资金情况的专项说明 | 2026-04-24 | Chinese | ||
| 39939076 | 赛伦生物：关于召开2025年年度股东会的通知 | 2026-04-24 | Chinese | ||
| 39939075 | 赛伦生物：2025年度董事会审计委员会履职情况报告 | 2026-04-24 | Chinese | ||
| 39939061 | 赛伦生物：董事会关于独立董事独立性自查情况的专项报告 | 2026-04-24 | Chinese | ||
| 39939059 | 方正证券承销保荐有限责任公司关于上海赛伦生物技术股份有限公司2025年度募集资金存放、管理与实际使用情况的专项核查意见 | 2026-04-24 | Chinese | ||
Market data
Market data not available
Price history
Peer group · Manufacture of pharmaceuticals, medicinal chemical and botanical products
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
13260917 Canada Inc.
Biotech developing oral small molecules to restore muscle s…
|
MSCL | CA | Manufacturing |
|
1608557 Ontario Inc.
Biopharmaceutical company dedicated to R&D, discovery, and …
|
OTROQ | CA | Manufacturing |
|
3B BlackBio Dx Limited
Develops molecular diagnostic kits for oncology, infectious…
|
3BBLACKBIO | IN | Manufacturing |
|
3D Medicines Inc.
Commercial-stage biopharma specializing in next-generation …
|
1244 | HK | Manufacturing |
|
3SBio Inc.
Biopharmaceutical enterprise specializing in R&D, productio…
|
1530 | KY | Manufacturing |
|
4BASEBIO PLC
Manufactures GMP-grade synthetic DNA for next-generation th…
|
4BB | GB | Manufacturing |
|
4D Molecular Therapeutics, Inc.
Develops genetic medicines using AAV vectors for ophthalmol…
|
FDMT | US | Manufacturing |
|
4Front Ventures Corp.
Vertically integrated cannabis operator managing cultivatio…
|
FFNT | CA | Manufacturing |
|
4SC AG
Biopharmaceutical company with no products under developmen…
|
VSC | DE | Manufacturing |
|
60 DEGREES PHARMACEUTICALS, INC.
Develops and commercializes medicines for infectious diseas…
|
SXTP | US | Manufacturing |
SHANGHAI SERUM BIO-TECHNOLOGY CO., LTD. via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/58198/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=58198 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=58198 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=58198 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 58198}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for SHANGHAI SERUM BIO-TECHNOLOGY CO., LTD. (id: 58198)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.